1. P44 Dupilumab reduces exacerbations and improves lung function in uncontrolled, moderate-to-severe asthma patients regardless of prior exacerbation history in the phase 3 LIBERTY ASTHMA QUEST study. (December 2018) Authors: Pavord, I; Ford, LB; Corren, J; Kuna, P; Dong, Q; Staudinger, H; Maroni, J; Rowe, P; Rout, R; Amin, N; Akinlade, B; Graham, NMH; Teper, A Journal: Thorax Issue: Volume 73(2018)Supplement 4 Page Start: A121 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P67: LONG‐TERM MANAGEMENT OF MODERATE‐TO‐SEVERE ATOPIC DERMATITIS WITH DUPILUMAB AND CONCOMITANT TOPICAL CORTICOSTEROIDS: A 1‐YEAR RANDOMIZED, PLACEBO‐CONTROLLED PHASE 3 TRIAL (CHRONOS). (7th September 2017) Authors: Blauvelt, A; Gooderham, M; Foley, P; CEM, Griffiths; Cather, JC; de Bruin‐Weller, M; Zhu, X; Akinlade, B; NMH, Graham; Pirozzi, G; Shumel, B Journal: Internal medicine journal Issue: Volume 47(2017)Supplement 5 Page Start: 25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P67: LONG‐TERM MANAGEMENT OF MODERATE‐TO‐SEVERE ATOPIC DERMATITIS WITH DUPILUMAB AND CONCOMITANT TOPICAL CORTICOSTEROIDS: A 1‐YEAR RANDOMIZED, PLACEBO‐CONTROLLED PHASE 3 TRIAL (CHRONOS). (September 2017) Authors: Blauvelt, A; Gooderham, M; Foley, P; CEM, Griffiths; Cather, JC; de Bruin‐Weller, M; Zhu, X; Akinlade, B; NMH, Graham; Pirozzi, G; Shumel, B Journal: Internal medicine journal Issue: Volume 47(2017)Supplement 5 Page Start: 25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. S126 Dupilumab efficacy in children with uncontrolled type 2 asthma analyzed by baseline high or medium ICS dose: LIBERTY ASTHMA VOYAGE study. (11th November 2022) Authors: Maspero, JF; Antila, MA; Jean, N; Deschildre, A; Bacharier, LB; Altincatal, A; Rimington, T; Laws, E; Akinlade, B; Radwan, A; Jacob-Nara, JA; Deniz, Y; Rowe, PJ; Lederer, DJ; Hardin, M Journal: Thorax Issue: Volume 77(2022)Supplement 1 Page Start: A77 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. S78 Dupilumab reduces risk of severe exacerbations and improves FEV1 regardless of baseline disease severity in patients with uncontrolled, moderate-to-severe asthma: data from the phase 3 LIBERTY ASTHMA QUEST study. (December 2018) Authors: Pavord, I; Papi, A; Wenzel, S; Park, HS; Rice, M; Staudinger, H; Maroni, J; Rowe, P; Rout, R; Amin, N; Akinlade, B; Graham, NMH; Teper, A Journal: Thorax Issue: Volume 73(2018)Supplement 4 Page Start: A48 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗